EIKN (NASDAQ:EIKN) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of EIKN (NASDAQ:EIKN) in a report released on Monday,Benzinga reports. The brokerage set an “overweight” rating and a $29.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 110.45% from the company’s current price.

A number of other research firms also recently commented on EIKN. Wall Street Zen upgraded EIKN to a “hold” rating in a report on Monday, February 16th. Morgan Stanley assumed coverage on EIKN in a research note on Monday. They set an “overweight” rating and a $32.00 price target for the company. Bank of America started coverage on EIKN in a research note on Monday. They issued a “buy” rating and a $34.00 price objective on the stock. Wedbush started coverage on shares of EIKN in a research report on Thursday. They set an “underperform” rating and a $7.00 target price for the company. Finally, Mizuho initiated coverage on shares of EIKN in a research report on Monday. They set an “outperform” rating and a $26.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.60.

EIKN Trading Up 1.0%

Shares of EIKN stock opened at $13.78 on Monday. EIKN has a 1-year low of $13.28 and a 1-year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.